Author: admin

Thailand’s Ministry of Commerce Unveils “Timeless Thai Taste 2025” Campaign

The goal of the campaign is to elevate national soft power in the U.S., promoting Thai Select cuisine and Thai BL series to drive the creative economy.

The Department of International Trade Promotion (DITP), under the Ministry of Commerce, is set to launch “Timeless Thai Taste 2025,” a landmark initiative aimed at advancing Thailand’s creative economy through the strategic deployment of cultural soft power. By uniting the culinary excellence of Thai cuisine with the global appeal of Thai entertainment, the campaign seeks to build brand awareness and boost export value in the United States. The program will roll out from July 9–14, 2025, across three key American cities: Los Angeles, Miami, and New York.

The initiative places Thai SELECT — the official certification for authentic Thai restaurants abroad — at its core, promoting Thailand’s culinary prestige on the international stage. Simultaneously, it taps into the worldwide popularity of Thai Boys’ Love (BL) series, a genre with a devoted fanbase, to reintroduce Thai cultural narratives through a modern, globally resonant lens.

More than ten celebrated actors from acclaimed series — including the rising stars of Shine — will headline the campaign, bridging fans and culture through exclusive meet-and-greets, live talks, and photo opportunities. The event also features a curated showcase of over 26 Thai SELECT-certified restaurants, offering signature dishes and iconic Thai beverages to reinforce the taste, quality, and international standards of Thai cuisine.

Additional highlights include live cooking demonstrations by professional chefs, premium ingredient showcases, and insight exhibitions on expanding into the U.S. food and cultural markets. A business matching zone will facilitate direct engagements between Thai producers and local importers, paving new channels for trade and collaboration.

“This campaign reaffirms Thailand’s leadership in Southeast Asia’s food and entertainment sectors. Through the strategic use of soft power, we aim to build international trust and generate long-term economic impact,” stated the Department of International Trade Promotion.

Event Schedule

  • Los Angeles – July 9, 2025 | Avalon Hollywood
  • Miami – July 11, 2025 | Hilton Miami Downtown
  • New York – July 14, 2025 | Melrose Ballroom


Admission is free. Pre-registration and event updates available via:

Twitter/X: @TimelessTHtaste

Email: timelessthaitaste.official@gmail.com

Media Contact
Company Name: Flowfusion Technology Company Limited
Contact Person: Montipa M.
Email: Send Email
City: Bangkok
Country: Thailand
Website: x.com/TimelessTHtaste

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thailand’s Ministry of Commerce Unveils “Timeless Thai Taste 2025” Campaign

Thermo Eco 41: Redefining Energy Renovation in Vendome and Beyond

Vendôme, France – In an era where energy efficiency is no longer a luxury but a necessity, Thermo Eco 41 stands out as a trusted partner for homeowners seeking comfort, sustainability, and real savings. With a mission rooted in professionalism, transparency, and dedication, Thermo Eco 41 has become a benchmark in the field of global and energy-focused renovations throughout Vendôme and surrounding areas.

More information can be found at https://thermoeco41.fr.

A Complete Approach: From Understanding to Execution

At Thermo Eco 41, the philosophy is simple: your comfort is our profession. This isn’t a catchy slogan; it’s the guiding principle behind every project. From the first meeting to the final touches, the team ensures that each renovation reflects both the client’s vision and the highest technical standards.

Understanding Your Unique Needs

Before proposing any solution, Thermo Eco 41 prioritizes listening and understanding. Each project begins with a thorough technical visit, during which experts:

  • Analyze the existing condition of your home

  • Assess thermal bridges, insulation deficits, and system inefficiencies

  • Understand your comfort priorities and budget

  • Identify constraints and potential optimizations

This in-depth approach guarantees tailored recommendations without overpromising unrealistic gains or hidden costs.

Advising with Clarity and Integrity

Once the evaluation is complete, Thermo Eco 41 provides clear, detailed estimates, outlining the scope, materials, expected results, and investment required. Every proposal is technically sound and financially coherent, ensuring no surprises along the way.

To make your renovation journey even smoother, the team guides you step by step in obtaining eligible subsidies and financial aid, helping you maximize available support for energy-efficient improvements.

Coordinating Every Stage with Precision

Unlike many contractors who rely heavily on sub-contractors, Thermo Eco 41’s in-house specialists manage and execute the most critical parts of the work themselves. When other trusted partners are needed, you remain informed:

  • Who is intervening

  • When each phase occurs

  • How the work will be delivered

From start to finish, you benefit from a single, reliable point of contact, ensuring total transparency and peace of mind.

Six Core Areas of Expertise

Thermo Eco 41 brings together a team skilled across multiple trades, making it a true entreprise tous corps d’état capable of transforming your home holistically.

1. Interior Thermal Insulation & Plasterboard (Placoplâtre)

Interior insulation remains a cornerstone of energy savings. Whether you wish to insulate walls, attics, sloped ceilings, or floors, Thermo Eco 41 offers advanced techniques to:

  • Improve your home’s thermal performance

  • Enhance acoustic comfort

  • Preserve living space aesthetics

Each installation is precise and compliant with the latest standards.

2. External Thermal Insulation (ITE)

Thermo Eco 41 specializes in comprehensive exterior insulation systems, wrapping your home in an efficient thermal envelope that delivers:

  • Cooler interiors in summer

  • Warmer spaces in winter

  • Significant energy savings year-round

Beyond performance, external insulation improves your property’s facade, blending beauty and functionality.

3. Thermodynamic Water Heaters

Whether you’re replacing an outdated system or installing a new one, thermodynamic water heaters provide high-efficiency hot water solutions. Thermo Eco 41’s experts ensure:

  • Proper sizing according to household needs

  • Seamless integration into existing networks

  • Reliable performance and reduced energy bills


4. Heat Pumps (Pompes à Chaleur)

Heat pumps have become an essential component of sustainable heating and cooling strategies. Thermo Eco 41 offers:

  • Installation of high-efficiency systems

  • Replacement of old, energy-intensive units

  • Personalized guidance to optimize performance

These solutions not only improve comfort but also significantly reduce environmental impact.

5. Global Home Renovation

When it comes to large-scale transformation, Thermo Eco 41 manages the entire process:

  • Technical upgrades (insulation, ventilation, heating)

  • Coordination of trades and timelines

  • Accompaniment up to the final reception

Clients benefit from a truly integrated approach, reducing delays and maximizing results.

6. Project Supervision & Customer Support

Every project is reinforced by clear, free estimates and meticulous technical oversight. Throughout each phase, clients enjoy regular updates and a dedicated point of contact who ensures objectives are respected.

A Local Presence with a Broad Reach

Thermo Eco 41’s headquarters in Vendôme is at the heart of its operations. The company guarantees intervention within a 40 km radius and considers projects beyond this perimeter upon request.

This flexibility, combined with rigorous planning, allows Thermo Eco 41 to serve homeowners across the region without compromising the quality of service.

The DNA of Thermo Eco 41: Values That Inspire Confidence

Three core values define Thermo Eco 41’s success and the trust it earns from clients:

1. Transparency

From the first conversation to project delivery, Thermo Eco 41 is committed to clear communication. No vague promises, no hidden fees—only honest, realistic advice.

2. Expertise

Every member of the team is an experienced professional with up-to-date training in their trade. This expertise translates into flawless execution and sustainable results.

3. Commitment

Your project is as important to the Thermo Eco 41 team as it is to you. They are driven by a sincere commitment to improve your home’s performance, comfort, and value.

See the Results for Yourself

A picture is worth a thousand words. Thermo Eco 41 invites you to explore its gallery of completed projects, where you can witness:

  • Stunning facade transformations

  • Elegant interior insulation

  • Modern heating system installations

  • Complete home renovations that blend style and efficiency

These realizations demonstrate the company’s capacity to deliver on its promises with consistency and quality.

Testimonials: Customers Share Their Experience

Homeowners throughout Vendôme praise Thermo Eco 41 for their reliability, professionalism, and human touch. Here are just a few sentiments echoed by satisfied clients:

  • “Thermo Eco 41 transformed our cold, inefficient house into a warm, comfortable home. The team was attentive and transparent throughout.”

  • “We appreciated the clarity of their quote and the meticulous planning. Every step was explained, and the result exceeded our expectations.”

  • “From insulation to heat pump installation, everything was handled with skill and professionalism. Highly recommended.”


Ready to Transform Your Home?

If you’re considering an energy renovation or a comprehensive refurbishment, Thermo Eco 41 is ready to help. Contact the team to schedule your free technical visit and discover how your project can become a reality.

Media Contact
Company Name: Thermo Eco 41
Email: Send Email
Phone: 07 68 86 58 73
Country: France
Website: https://thermoeco41.fr

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thermo Eco 41: Redefining Energy Renovation in Vendome and Beyond

Moving Services in Hoboken, New Jersey: Introducing Emergency Same-Day Solutions for Residents in Urgent Situations

HOBOKEN, NEW JERSEY – Ample Moving announces the expansion of their emergency relocation capabilities, now offering same-day moving solutions for residents and businesses facing urgent or unexpected moving situations. This service enhancement addresses a critical need in the community for reliable, immediate moving assistance.

“Life doesn’t always give you weeks to plan a move,” explains Andy Novak, strategy consultant at Ample Moving. “Whether it’s a sudden job offer, lease termination, or other unforeseen circumstance, our team is now equipped to mobilize quickly and execute moves with the same professionalism and care that we bring to planned relocations.”

The company’s reputation as trusted long distance movers in Hoboken, NJ now extends to emergency situations, with their rapid-response team able to handle both local and long-distance urgent moves. This initiative reinforces Ample Moving’s commitment to comprehensive service offerings that meet diverse client needs.

Customers requiring emergency moving assistance can expect the same transparency and professionalism that distinguishes Ample Moving as a premier local moving company in Hoboken, NJ. The company maintains its no-hidden-fees policy even for same-day services, providing detailed cost breakdowns before work begins.

Ample Moving’s emergency service includes specialized handling for delicate items. As a Hoboken, New Jersey moving company, their trained experts properly secure and transport everything from electronics to antiques, even under tight timeframes. Their comprehensive approach ensures nothing is overlooked, even when time is limited.

The introduction of same-day services complements Ample Moving’s existing moving services in Hoboken, New Jersey portfolio, which includes residential, commercial, packing, and specialty item transportation. Their Jersey City headquarters allows for quick deployment throughout New Jersey and surrounding areas.

For residents facing unexpected moving needs, visit https://amplemoving.com or call immediately to check availability for same-day moving services and receive immediate assistance from Ample Moving’s professional team. Their dedicated customer support line is staffed around the clock to respond to urgent moving requests within minutes.

Media Contact
Company Name: Ample Moving
Contact Person: Media Relations
Email: Send Email
Phone: 1-201-721-5777
Address:9 Linden Ave
City: Jersey City
State: New Jersey 07305
Country: United States
Website: https://amplemoving.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Moving Services in Hoboken, New Jersey: Introducing Emergency Same-Day Solutions for Residents in Urgent Situations

Top Realtor in San Diego, CA, Delivers Comprehensive Real Estate Solutions Through a Client-Centered Approach

Chase Penrose is excited to introduce a new era of comprehensive real estate solutions designed for San Diego’s discerning homebuyers and sellers. By integrating innovative strategies with a commitment to service excellence, his firm continues to thrive in a competitive market. His focus remains on delivering tailored experiences that meet evolving client needs.

Chase began his real estate journey at 16 and became a licensed agent in 2017. Incorporated as a business in 2022, his path from assisting top-producing agents to founding his own firm reflects a blend of youthful ambition and proven expertise. His deep passion for San Diego and commitment to personalized service set him apart in the industry.

Central to his approach is a dedication to understanding each client’s unique goals. By listening closely and tailoring strategies, Chase turns challenges into opportunities. His hands-on method ensures every transaction is managed with precision. Recognized as a trusted real estate listing agent in San Diego, CA, he consistently delivers results that build lasting client relationships.

Embracing innovative marketing and technology, Chase enhances the visibility of every property. His expert staging and targeted promotion highlight each home’s best features, ensuring competitive positioning in the market. This attention to detail has earned him a reputation as a skilled real estate selling agent in San Diego, CA, driving success for property sellers.

Chase’s competitive edge stems from his strategic vision and market insight. His creative problem-solving and tailored strategies consistently deliver superior outcomes. Clients value his honest advice and dedicated support, making him a preferred choice in the real estate field. This approach solidifies his reputation as a dedicated Realtor agent in San Diego, CA.

Reflecting on his journey, Chase Penrose, Realtor, shares, “I am committed to delivering a client-centered experience that transforms real estate dreams into reality.” His passion for excellence and innovative strategies continue to inspire both new and seasoned clients. Discover exceptional service and unparalleled results. Embrace the opportunity to work with a top San Diego, CA Realtor and experience the difference firsthand by visiting https://www.chasepenrose.com today for more information.

Media Contact
Company Name: Chase Penrose – Top Realtor in San Diego, CA
Contact Person: Chase Penrose
Email: Send Email
Phone: +1 858-900-3433
Address:8889 Rio San Diego Dr, Ste 200
City: San Diego
State: California 92108
Country: United States
Website: https://www.chasepenrose.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor in San Diego, CA, Delivers Comprehensive Real Estate Solutions Through a Client-Centered Approach

IgA Nephropathy Therapeutic Market Expected to Witness Significant Growth By 2034, Driven by Recent FDA Approval and Novel Therapeutics | DelveInsight

“IgA Nephropathy Market Insight, Epidemiology And Market Forecast – 2034”
The IgA Nephropathy (IgAN) treatment market is poised for substantial growth, driven by the introduction of innovative therapies and the increasing prevalence of this chronic kidney disease. Leading IgAN companies, including Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., and Vera Therapeutics, among others, are at the forefront of transforming the IgAN treatment landscape.

DelveInsight’s “IgA Nephropathy Market Insight, Epidemiology And Market Forecast – 2034” report provides an extensive analysis of IgA nephropathy (IgAN), including historical and forecasted epidemiology data, current treatment practices, emerging therapies, and market projections across the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan). The report indicates that the IgA Nephropathy market is anticipated to grow at a significant CAGR during the study period (2020-2034), driven by increasing disease awareness, improved diagnostic capabilities, and the launch of novel therapeutic options targeting specific pathways involved in IgAN pathogenesis.

This market expansion reflects growing recognition of IgAN as a significant cause of end-stage renal disease (ESRD) globally and the urgent need for effective disease-modifying treatments beyond conventional supportive care.

IgA nephropathy, also known as Berger disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli—the tiny filtering units within the kidneys. This abnormal buildup triggers inflammation and progressive damage, impairing the kidneys’ ability to filter waste and excess fluid from the blood. Over time, IgA nephropathy can lead to chronic kidney disease or even kidney failure in a significant subset of patients, making it one of the most common causes of glomerulonephritis worldwide.

Download the IgA nephropathy market report to understand which factors are driving the IgA nephropathy therapeutic market @ IgA Nephropathy Market Trends.

According to DelveInsight’s epidemiological analysis, the total diagnosed prevalent population of IgA Nephropathy in the 7MM comprised approximately 400K cases in 2023. Japan accounted for the highest proportion of IgAN diagnosed prevalent cases, representing about 45% of the total patient population across the studied regions. Furthermore, the data reveals a notable gender disparity, with IgA nephropathy showing male predominance in the United States in 2023. This epidemiological profile underscores the substantial patient population that could benefit from emerging targeted therapies, thereby driving market growth in the forecast period.

Discover evolving trends in the IgAN patient pool forecasts @ IgAN Epidemiology Analysis.

The IgA nephropathy pipeline is robust, featuring multiple promising candidates in late-stage development that target various pathophysiological mechanisms. Current clinical development programs focus on innovative approaches, including complement pathway inhibition, B-cell modulation, targeted immunosuppression, and novel anti-inflammatory agents. These emerging therapies address the multifaceted nature of IgAN pathogenesis and offer improved efficacy, safety profiles, and quality of life outcomes compared to conventional treatments. The diversification of therapeutic approaches reflects growing understanding of the complex immunological mechanisms underlying IgAN and represents a paradigm shift toward precision medicine in nephrology.

The IgA nephropathy treatment landscape has witnessed significant advancements in recent years, with several breakthrough approvals reshaping clinical practice and further expanding this significant market. In September 2024, Travere Therapeutics achieved a major milestone with the full FDA approval of FILSPARI to slow the decline in kidney function in adults with primary IgA nephropathy. This approval followed an earlier accelerated approval based on proteinuria reduction, with full approval supported by positive long-term data from the PROTECT Study demonstrating sustained clinical benefits. Additionally, FILSPARI received conditional marketing authorization from the European Commission in April 2024 for treating adults with primary IgAN with significant proteinuria.

Discover evolving trends in the IgA Nephropathy treatment landscape @ IgA Nephropathy Therapies Market.

Moreover, in April 2025, Novartis (SWX: NOVN) received FDA accelerated approval for VANRAFIA, making it the first and only selective endothelin receptor antagonist approved to reduce proteinuria in adults with primary IgA nephropathy. This approval is based on the ongoing Phase III ALIGN study, which showed that patients receiving Vanrafia in combination with a RAS inhibitor experienced a clinically meaningful and statistically significant proteinuria reduction of 36.1% (P<0.0001) compared to placebo.

In March 2025, Arrowhead Pharmaceuticals’ RNAi therapy ARO-C3 demonstrated promising results in a Phase I/II trial for IgA nephropathy, with a mean 89% reduction in complement protein C3 and a 41% decrease in proteinuria (UPCR) after 24 weeks. Administered subcutaneously every three months, the treatment showed sustained suppression of alternative complement pathway activity (≥87% C3 reduction) and was well-tolerated, with only mild side effects like headaches and coughs reported. Full data will be presented at a medical conference in late 2025, positioning ARO-C3 as a potential quarterly treatment targeting the root cause of IgAN.

Also, the European Commission converted accelerated approval of FILSPARI (Travere Therapeutics) to standard approval in April 2025.

Discover recent advancements in the IgA Nephropathy treatment landscape @ IgA Nephropathy Recent Developments.

Despite therapeutic advances, significant unmet needs persist in the IgA nephropathy treatment landscape. These include the need for earlier disease detection, biomarkers to predict disease progression and treatment response, and therapies that can reverse existing kidney damage rather than merely slowing disease progression. Moreover, improving access to specialized care and novel therapies remains challenging, particularly in regions with limited healthcare resources. DelveInsight’s analysis highlights that addressing these unmet needs will be crucial for optimizing patient outcomes and maximizing the market potential for emerging IgAN therapies.

Looking ahead, the IgA nephropathy market is expected to witness transformative growth. The integration of biomarkers into clinical practice and the development of combination therapeutic strategies targeting multiple pathways simultaneously represent promising future directions. Additionally, ongoing research into the genetic and molecular determinants of IgAN susceptibility and progression may pave the way for personalized treatment approaches, further revolutionizing the management of this chronic kidney disease and enhancing long-term patient outcomes across the global IgAN landscape.

Table of Contents

1. Key Insights

2. Report Introduction

3. IgAN Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Methodology

8. IgAN Epidemiology and Patient Population

9. IgAN Patient Journey

10. IgAN Marketed Drugs

11. IgAN Emerging Drugs

12. IgAN – 7MM Market Analysis

13. KOL Views

14. IgAN Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IgA Nephropathy Therapeutic Market Expected to Witness Significant Growth By 2034, Driven by Recent FDA Approval and Novel Therapeutics | DelveInsight

Las Vegas, NV Realtor Notes the Importance of Choosing the Right Agent for a Successful Real Estate Journey

Cynthia Glickman, a distinguished Las Vegas, NV Realtor, is sharing valuable advice for clients navigating the complex world of real estate. With over two decades of experience and a background as a math professor, Glickman brings exceptional analytical abilities and a strategic mindset to her work, ensuring clients are well-prepared for every step of their journey.

“Choosing the right agent is one of the most important decisions you can make when buying or selling a home,” says Glickman. “It’s not just about finding someone with experience; it’s about choosing an agent who understands your unique needs, communicates effectively, and acts in your best interests.”

As a trusted Realtor in Las Vegas, NV, Glickman advises clients to prioritize an agent’s track record, communication style, and market knowledge. These qualities, coupled with her strategic approach, have made her a sought-after expert for clients ranging from first-time buyers to seasoned investors. Her ability to analyze market trends and negotiate favorable terms gives her clients a distinct advantage.

Glickman also emphasizes the importance of empathy and attentiveness in an agent-client relationship. As a dedicated real estate professional, she ensures that her clients feel supported and confident throughout the process. Her tailored strategies and clear communication help clients navigate even the most complex transactions with ease.

For sellers, Glickman’s role as a real estate listing agent in Las Vegas, NV includes providing expert guidance on market preparation and pricing. With her meticulous attention to detail and strategic staging advice, sellers can maximize their property’s value and attract serious buyers.

To work with an experienced agent who combines professionalism with a personal touch, contact Cynthia Glickman, Las Vegas, NV Realtor, at https://cynthiaglickmanrealtor.com/. Let her strategic mindset and dedication to client success guide you through your next real estate journey with confidence and ease.

Media Contact
Company Name: Cynthia Glickman | Real Estate Agent in Las Vegas, NV | Windermere Real Estate
Contact Person: Cynthia Glickman
Email: Send Email
Phone: +1 702-829-2424
Address:10845 Griffith Peak Dr
City: Las Vegas
State: Nevada 89135
Country: United States
Website: http://windermereexcellence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Las Vegas, NV Realtor Notes the Importance of Choosing the Right Agent for a Successful Real Estate Journey

Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hepatitis D Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hepatitis D Pipeline Outlook

Key Takeaways from the Hepatitis D Pipeline Report

  • In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups – an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016.
  • In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
  • DelveInsight’s Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment.
  • The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
  • Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.

Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs

Hepatitis D Emerging Drugs Profile

  • Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals

Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D.

  • Brelovitug: Bluejay Therapeutics

Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D.

  • RBD1016: Ribocure Pharmaceuticals AB

RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D.

The Hepatitis D Pipeline Report Provides Insights into-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment.
  • Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market

Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight’s detailed report now! @ New Hepatitis D Drugs

Hepatitis D Companies

Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Hepatitis D Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatitis D Market Drivers and Barriers

Scope of the Hepatitis D Pipeline Report

  • Coverage- Global
  • Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
  • Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
  • Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Hepatitis D: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatitis D– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. Brelovitug: Bluejay Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hepatitis D Key Companies
  21. Hepatitis D Key Products
  22. Hepatitis D- Unmet Needs
  23. Hepatitis D- Market Drivers and Barriers
  24. Hepatitis D- Future Perspectives and Conclusion
  25. Hepatitis D Analyst Views
  26. Hepatitis D Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Mucopolysaccharidosis I Treatment Market Set for Robust Growth Through 2034, Driven by Emerging Gene Therapies and Pipeline Developments | DelveInsight

The Mucopolysaccharidosis I treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, REGENXBIO, Nippon Shinyaku, and Immusoft, among others.

DelveInsight’s “Mucopolysaccharidosis Type I Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the MPS I treatment market, historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and MPS I market forecasts through 2034, providing crucial insights into the MPS I therapeutic landscape.

According to DelveInsight’s analysis, the Mucopolysaccharidosis I Market in the 7MM was valued at approximately USD 145 million in 2024. Over the forecast period from 2025 to 2034, this market is projected to grow at a CAGR of 8.0%, driven by the launch of innovative Mucopolysaccharidosis I Therapies, including OTL-203, Lepunafusp alfa (JR-171), and RGX-111.

Download the Mucopolysaccharidosis I Market report to understand which factors are driving the Mucopolysaccharidosis I therapeutic market trends.

Epidemiology Insights Reveal Significant Patient Population

According to DelveInsight’s estimates, in 2024, there were approximately 660 Mucopolysaccharidosis I diagnosed prevalent cases in the 7MM. Of these, EU4 and the UK accounted for the largest cases with nearly 60% of the total Mucopolysaccharidosis I cases across 7MM, while the United States accounted for 36% of the cases with approximately 240 cases, and Japan represented 4% of the cases with around 20 cases.

In 2024, the UK reported the highest number of Mucopolysaccharidosis I Diagnosed Prevalent Cases among EU4 and the UK, with approximately 110 cases. Italy followed with nearly 75 cases, while Spain recorded the lowest diagnosed prevalent cases, with nearly 60 cases.

The DelveInsight report further categorizes the Mucopolysaccharidosis I patient population into severity-specific groups, differentiating between Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome, with Hurler syndrome representing the most severe form affecting an estimated 1 in every 100,000 newborns.

Discover evolving trends in the Mucopolysaccharidosis I patient pool forecasts through epidemiological analysis.

Current Treatment Landscape Dominated by Single Therapy

Currently, in the Mucopolysaccharidosis I market, BioMarin Pharmaceutical and Sanofi are the only players, offering ALDURAZYME (laronidase). This Enzyme replacement therapy (ERT) is approved for patients with Hurler and Hurler-Scheie forms of MPS I, as well as those with the Scheie form who experience moderate to severe symptoms. ALDURAZYME is a recombinant form of the human enzyme IDUA and was first approved in the US in April 2003, followed by EU4 and the UK in June 2003, and Japan in 2006.

As per the estimates, among the current Mucopolysaccharidosis I Treatment options, ALDURAZYME hold the largest Mucopolysaccharidosis I drugs market share, generating approximately USD 145 million in revenue in 2024 across the 7MM. Although its patent has expired, no biosimilar or alternative biologic has been approved yet, highlighting a significant gap in treatment options for MPS I patients.

Promising Pipeline Developments Signal Market Transformation

The Mucopolysaccharidosis I pipeline is robust and promising, with several novel treatments in development addressing critical unmet needs. OTL-203, developed by Orchard Therapeutics and Kyowa Kirin, is a one-time gene therapy for MPS IH, using a patient’s own hematopoietic stem and progenitor cells. These cells are genetically modified ex vivo with a lentiviral vector carrying functional IDUA complementary DNA, restoring enzyme expression and reducing GAG accumulation. The therapy is currently in Phase III trials in North America and Europe, with anticipated US application in 2028 and potential approval in 2029 with priority review.

Lepunafusp alfa (JR-171), developed by JCR Pharmaceuticals, represents an advanced ERT designed to address central nervous system complications in MPS I. This recombinant fusion protein combines an antibody targeting the human transferrin receptor with IDUA, efficiently crossing the Blood-Brain Barrier through transferrin receptor-mediated transcytosis. The therapy has completed a 13-week Phase I/II clinical trial in Japan and the US, with an extension study ongoing.

RGX-111, developed by REGENXBIO and Nippon Shinyaku, is an investigational gene therapy that delivers a functional IDUA gene directly to the CNS, promoting enzyme production in brain cells. This approach aims to slow or prevent cognitive decline and neurological impairments associated with MPS I. Recent developments show promising biological activity and safety in ongoing Phase I/II trials.

Discover recent advancements in the Mucopolysaccharidosis I treatment landscape through ongoing clinical development programs.

Future Opportunities

The future of MPS I treatment is poised for significant advancements, driven by ongoing research and innovative therapies. Emerging treatments have the potential to address unmet needs, improve effectiveness, and enhance outcomes. As research progresses, integrating novel strategies will lead to a more comprehensive and effective approach to managing MPS I in the future.

Looking ahead, there is a significant need for new Mucopolysaccharidosis I treatments, as current therapies have limitations, including boxed warnings. The promising pipeline, including OTL-203, Lepunafusp alfa (JR-171), RGX-111, and Iduronicrin genleukocel-T (ISP-001), offers novel approaches that have the potential to reshape the treatment landscape by improving patient outcomes and reducing the limitations of existing treatments.

DelveInsight’s analysis underscores that despite current therapeutic limitations, substantial opportunities remain for developing more effective treatment options that can achieve better outcomes and improved quality of life for MPS I patients worldwide. As research continues and awareness grows, the Mucopolysaccharidosis I market is poised for remarkable expansion and therapeutic innovation.

Table of Contents

1. Key Insights

2. Report Introduction

3. Mucopolysaccharidosis I Market Overview at a Glance

4. Mucopolysaccharidosis I Market: Future Perspective

5. Executive Summary of Mucopolysaccharidosis I

6. Key Events

7. Mucopolysaccharidosis I Background and Overview

8. Mucopolysaccharidosis I Market Epidemiology and Patient Population

9. Mucopolysaccharidosis I Patient Journey

10. Mucopolysaccharidosis I Marketed Drugs

11. Mucopolysaccharidosis I Emerging Drugs

12. Mucopolysaccharidosis I: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Mucopolysaccharidosis I Market Unmet Needs

15. SWOT Analysis

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Mucopolysaccharidosis I Pipeline Insight

Mucopolysaccharidosis I pipeline insight provides comprehensive insights about the Mucopolysaccharidosis I pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Mucopolysaccharidosis I companies, including Takeda, BioMarin, Ultragenyx Pharmaceutical, Sarepta Therapeutics, Inventiva, GC Pharma, JCR Pharmaceuticals, REGENXBIO, Sangamo Therapeutics, Denali Therapeutics, ArmaGen, Chiesi, Eloxx Pharmaceuticals, Esteve, Greencross, Immusoft Corporation, and Paradigm Biopharmaceuticals Ltd., among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mucopolysaccharidosis I Treatment Market Set for Robust Growth Through 2034, Driven by Emerging Gene Therapies and Pipeline Developments | DelveInsight

Ocular Hypertension Market Set for Steady Growth Through 2034, Driven by Novel Therapies and Aging Population Demographics | DelveInsight

“Ocular Hypertension Market Insight, Epidemiology And Market Forecast – 2034”
The ocular hypertension market is experiencing steady expansion, driven by increasing prevalence of chronic conditions, an aging population, and breakthrough therapies from key pharmaceutical players, including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, and Noveome Biotherapeutics, among others.

DelveInsight’s “Ocular Hypertension Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the ocular hypertension treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and ocular hypertension market forecasts through 2034, providing crucial insights for stakeholders in the ocular hypertension therapeutic area.

According to DelveInsight’s analysis, the ocular hypertension market in the 7MM is expected to grow at a CAGR of approximately 3% during the forecast period from 2025 to 2034, driven by the introduction of novel therapies such as NCX 470, QLS-111, and ST266, alongside a growing aging population.

Download the Ocular Hypertension Market report to understand which factors are driving the ocular hypertension therapeutic market trends.

According to DelveInsight’s estimates, in 2024, there were approximately 13 million cases diagnosed with ocular hypertension in the 7MM, with a total of 21 million prevalent cases. The United States accounted for 41% of the diagnosed cases, while EU4 and the UK represented 38% and Japan represented 21% of the cases. Both prevalence and diagnostic rates are projected to increase over the forecast period (2025–2034).

The DelveInsight report further categorizes the ocular hypertension patient population into several groups for analysis, including gender-specific prevalence and age-specific prevalence cases. In 2024, females were more affected by ocular hypertension in the US compared to males. Additionally, Japan saw the highest prevalence of ocular hypertension among individuals aged 80 and above, followed by those in the lower age groups.

Discover evolving trends in the Ocular Hypertension patient pool forecasts.

The current ocular hypertension treatment landscape involves both pharmacological and surgical therapies, with the market segmented into various classes: prostaglandin analogs (PGAs), beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, RHO kinase inhibitors, and combination therapies. VYZULTA (latanoprostene bunod ophthalmic solution) by Bausch + Lomb represents a significant advancement, offering a dual mechanism of action as a prostaglandin analog designed to manage IOP in patients with open-angle glaucoma or ocular hypertension.

RHOPRESSA (netarsudil ophthalmic solution) by Alcon/Santen Pharmaceutical, a 0.02% Rho kinase inhibitor, lowers intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork, reducing aqueous humor production, and lowering episcleral venous pressure. Meanwhile, DURYSTA (bimatoprost implant) by AbbVie delivers a biodegradable implant containing 10 µg of bimatoprost via a single intracameral administration.

The ocular hypertension pipeline shows promising developments with several novel treatments in clinical stages. NCX 470 by Nicox/Kowa is an innovative eye drop formulation combining nitric oxide and bimatoprost to lower IOP through dual mechanisms, with topline results from the Denali Phase III trial expected in the second half of 2025. QLS-111 by Qlaris Bio, based on an ATP-sensitive potassium channel modulator platform, has shown persistent IOP reduction without causing hyperemia, with two US Phase II trials initiated in April 2024. ST266 by Noveome Biotherapeutics, a cell-free biologic containing hundreds of proteins and factors involved in cellular healing and neuroprotection, has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies.

Recent developments highlight the dynamic nature of the ocular hypertension treatment landscape. The US NDA for NCX 470 is expected to be submitted in H1 2026, while Qlaris Bio secured USD 24 million in Series B funding to support QLS-111 development. Further clinical milestone updates and regulatory submissions are anticipated throughout the forecast period.

Discover recent advancements in the Ocular Hypertension treatment landscape.

The ocular hypertension treatment market is highly competitive, with major players including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, Noveome Biotherapeutics, and other pharmaceutical companies advancing innovative therapies through robust R&D and strategic partnerships. The market landscape continues to evolve with companies pursuing clinical trials and strategic partnerships to introduce innovative treatment approaches and expand their market share.

Looking ahead, the ocular hypertension market faces challenges related to the variability in angle configurations, necessitating varied surgical approaches for effective intraocular pressure management. However, future treatment opportunities are expanding with a focus on pharmacological advancements and innovative delivery methods, including neuroprotection approaches to preserve ocular health. New therapies such as rho kinase inhibitors and nitric oxide-donating PGAs focus on improving aqueous humor outflow, specifically targeting the trabecular meshwork.

DelveInsight’s analysis underscores that several unmet needs remain in ocular hypertension management, prompting continued innovation in treatment approaches. As the market evolves with novel therapeutic mechanisms and improved delivery systems, the ocular hypertension market is positioned for steady growth and therapeutic advancement, driven by demographic trends and ongoing clinical development activities.

Table of Contents

1. Key Insights

2. Report Introduction

3. Ocular Hypertension Market Overview at a Glance

4. Ocular Hypertension Market: Future Perspective

5. Executive Summary of Ocular Hypertension

6. Key Events

7. Ocular Hypertension Background and Overview

8. Ocular Hypertension Market Epidemiology and Patient Population

9. Ocular Hypertension Patient Journey

10. Ocular Hypertension Marketed Drugs

11. Ocular Hypertension Emerging Drugs

12. Ocular Hypertension: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Ocular Hypertension Market Unmet Needs

15. SWOT Analysis

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Ocular Hypertension Pipeline Insight

Ocular Hypertension pipeline insight provides comprehensive insights about the Ocular Hypertension pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ocular Hypertension companies, including Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, and Ocuphire Pharma, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ocular Hypertension Market Set for Steady Growth Through 2034, Driven by Novel Therapies and Aging Population Demographics | DelveInsight

Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight

DelveInsight’s, “Adrenocortical Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report

  • In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
  • DelveInsight’s Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
  • The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
  • Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.

Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs

Adrenocortical Carcinoma Emerging Drugs Profile

  • Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer.

  • Ipilimumab: Bristol-Myers Squibb

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.

The Adrenocortical Carcinoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
  • Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Adrenocortical Carcinoma Drugs

Adrenocortical Carcinoma Companies

Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Adrenocortical Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers

Scope of the Adrenocortical Carcinoma Market Report

  • Coverage- Global
  • Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
  • Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
  • Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Adrenocortical Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Adrenocortical Carcinoma– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Ipilimumab: Bristol-Myers Squibb
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. Relacorilant: Corcept Therapeutics
  12. Preclinical and Discovery Stage Products
  13. Drug name: Company name
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Adrenocortical Carcinoma Key Companies
  17. Adrenocortical Carcinoma Key Products
  18. Adrenocortical Carcinoma- Unmet Needs
  19. Adrenocortical Carcinoma- Market Drivers and Barriers
  20. Adrenocortical Carcinoma- Future Perspectives and Conclusion
  21. Adrenocortical Carcinoma Analyst Views
  22. Adrenocortical Carcinoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight